DDR1 and glioblastoma: While DDR1 inhibition is a novel therapeutic strategy against recurrent GBM in vitro, further validation of its in vivo and clinical efficacy is warranted, and the development of more DDR1-specific inhibitors holds promise as targeted therapies against GBM.